Duration of antimicrobial therapy in community acquired pneumonia: Less is more

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Pinzone, Marilia Rita ^a   Cacopardo, Bruno ^a   Abbo, Lilian ^b   Nunnari, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROCALCITONIN; PROTEIN PRECURSOR;

CLINICAL TRIAL (TOPIC); COMMUNITY ACQUIRED INFECTION; DRUG ADMINISTRATION; HUMAN; METABOLISM; PNEUMONIA; REVIEW;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PNEUMONIA; PROTEIN PRECURSORS;

EID: 84893833069     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/759138     Document Type: Review

References (45)

1. Donowitz G. R., Acute pneumonia. Mandell, Douglas, and Bennett's, Principles and Practice of Infectious Diseases 2010 Philadelphia, Pa, USA Churchill Livingstone, Elsevier 891 916
2. World Health Organization, The top 10 causes of death. 2012, http://www.who.int/mediacentre/factsheets/fs310/en/index.html#
3. Mandell L. A., Epidemiology and etiology of community-acquired pneumonia. Infectious Disease Clinics of North America 2004 18 4 761 776 10.1016/j.idc.2004.08.003 (Pubitemid 39536007)
4. Mandell L. A., Wunderink R. G., Anzueto A., Bartlett J. G., Campbell G. D., Dean N. C., Dowell S. F., File T. M. Jr., Musher D. M., Niederman M. S., Torres A., Whitney C. G., Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007 44 supplement 2 S27 S72 2-s2.0-33847155159 10.1086/511159 (Pubitemid 46290553)
5. Lim W. S., Baudouin S. V., George R. C., Hill A. T., Jamieson C., Le Jeune I., Macfarlane J. T., Read R. C., Roberts H. J., Levy M. L., Wani M., Woodhead M. A., BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009 64 3 1 55 10.1136/thx.2009.121434 2-s2.0-77349095417
6. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M., Ortqvist A., Schaberg T., Torres A., van der Heijden G., Read R., Verheij T. J. M., Guidelines for the management of adult lower respiratory tract infections-summary. Clinical Microbiology and Infection 2011 17 6 1 24 2-s2.0-80053284682 10.1111/j.1469-0691.2011.03602.x
7. Niederman M. S., Mandell L. A., Anzueto A., Bass J. B., Broughton W. A., Campbell G. D., Dean N., File T., Fine M. J., Gross P. A., Martinez F., Marrie T. J., Plouffe J. F., Ramirez J., Sarosi G. A., Torres A., Wilson R., Yu V. L., Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine 2001 163 7 1730 1754 2-s2.0-0034959819 (Pubitemid 32578779)
8. Bronzwaer S. L. A. M., Cars O., Udo Buchholz S. M., Goettsch W., Veldhuijzen Jacob L Kool I. K., Sprenger M. J. W., Degener J. E., A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerging Infectious Diseases 2002 8 3 278 282 2-s2.0-0036200188 (Pubitemid 34266265)
9. Goossens H., Ferech M., Vander Stichele R., Elseviers M., Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. The Lancet 2005 365 9459 579 587 2-s2.0-13844254907 10.1016/S0140-6736(05)17907-0 (Pubitemid 40247914)
10. Nicolau D. P., Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 2001 29 supplement 2 11 15 2-s2.0-0035661937 (Pubitemid 34001314)
11. Pankuch G., Jacobs M., Appelbaum P., Antipneumococcal activity of ertapenem compared to nine other compounds by time-kill. Proceedings of the Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy 2001 Chicago, Ill, USA abstract E-800 American Society for Microbiology 184
12. Pankuch G., Jacobs M., Appelbaum P., Time-kill analysis of the anti-pneumococcal activity of daptomycin compared with 8 other agents. Proceedings of the Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2002 San Diego, Calif, USA American Society for Microbiology 161
13. Lacy M. K., Lu W., Xu X., Tessier P. R., Nicolau D. P., Quintiliani R., Nightingale C. H., Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrobial Agents and Chemotherapy 1999 43 3 672 677 2-s2.0-0032978288 (Pubitemid 29109538)
14. El Moussaoui R., de Borgie C. A. J. M., Van Den Broek P., Hustinx W. N., Bresser P., Van Den Berk G. E. L., Poley J.-W., Van Den Berg B., Krouwels F. H., Bonten M. J. M., Weenink C., Bossuyt P. M. M., Speelman P., Opmeer B. C., Prins J. M., Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. British Medical Journal 2006 332 7554 1355 1358 2-s2.0-33745008356 (Pubitemid 44365348)
15. Léophonte P., Choutet P., Gaillat J., Petitpretz P., Portier H., Montestruc F., Pecking M., de Bels F., Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Medecine et Maladies Infectieuses 2002 32 7 369 381 2-s2.0-0036317746 10.1016/S0399-077X(02)00384-0 (Pubitemid 34763793)
16. Siegel R. E., Alicea M., Lee A., Blaiklock R., Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. American Journal of Therapeutics 1999 6 4 217 222 2-s2.0-0032783571 (Pubitemid 29342881)
17. Barman Balfour J. A., Figgitt D. P., Telithromycin. Drugs 2001 61 6 815 829 2-s2.0-0034980950 (Pubitemid 32507017)
18. Muller-Serieys C., Soler P., Cantalloube C., Lemaitre F., Hai Pham Gia H. P. G., Brunner F., Andremont A., Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrobial Agents and Chemotherapy 2001 45 11 3104 3108 2-s2.0-0034774476 10.1128/AAC.45.11.3104-3108.2001 (Pubitemid 32988835)
19. Namour F., Wessels D. H., Pascual M. H., Reynolds D., Sultan E., Lenfant B., Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrobial Agents and Chemotherapy 2001 45 1 170 175 2-s2.0-0035169214 10.1128/AAC.45.1.170-175.2001 (Pubitemid 32039110)
20. Tellier G., Chang J. R., Asche C. V., Lavin B., Stewart J., Sullivan S. D., Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days. Current Medical Research and Opinion 2004 20 5 739 747 2-s2.0-2542499533 10.1185/030079904125003610 (Pubitemid 38685020)
21. Bhavnani S. M., Andes D. R., Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005 25 5 717 740 2-s2.0-18044381726 10.1592/phco.25.5.717.63583 (Pubitemid 40604888)
22. File T. M. Jr., Mandell L. A., Tillotson G., Kostov K., Georgiev O., Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. Journal of Antimicrobial Chemotherapy 2007 60 1 112 120 2-s2.0-34447556820 10.1093/jac/dkm119 (Pubitemid 47073284)
23. Dunbar L. M., Wunderink R. G., Habib M. P., Smith L. G., Tenneberg A. M., Khashab M. M., Wiesinger B. A., Xiang J. X., Zadeikis N., Kahn J. B., High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clinical Infectious Diseases 2003 37 6 752 760 2-s2.0-0142187265 10.1086/377539 (Pubitemid 37153652)
24. Dimopoulos G., Matthaiou D. K., Karageorgopoulos D. E., Grammatikos A. P., Athanassa Z., Falagas M. E., Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008 68 13 1841 1854 2-s2.0-50249172762 10.2165/00003495-200868130-00004
25. Bohte R., Van't Wout J. W., Lobatto S., Blusse van Oud Alblas A., Boekhout M., Nauta E. H., Hermans J., Van den Broek P. J., Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1995 14 3 182 187 2-s2.0-0028916440
26. Brion J. P., Sedallian A., Le Noc P., Briffod J., Micoud M., Azithromycin veruss josamycin: treatment of eighty-nine acute pneumonia cases. Pathologie Biologie 1990 38 5, part 2 521 525 2-s2.0-0025280217
27. Kinasewitz G., Wood R. G., Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1991 10 10 872 877 2-s2.0-0025999735
28. O'Doherty B., Muller O., Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1998 17 12 828 833 2-s2.0-0032406880 10.1007/s100960050201 (Pubitemid 29219147)
29. Rizzato G., Montemurro L., Fraioli P., Montanari G., Fanti D., Pozzoli R., Magliano E., Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. European Respiratory Journal 1995 8 3 398 402 2-s2.0-0028934626
30. Schonwald S., Barsic B., Klinar I., Gunjaca M., Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scandinavian Journal of Infectious Diseases 1994 26 6 706 710 2-s2.0-0028560474
31. Schonwald S., Gunjaca M., Kolacny-Babic L., Car V., Gosev M., Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. Journal of Antimicrobial Chemotherapy 1990 25 123 126 2-s2.0-0025134230 (Pubitemid 20043958)
32. D'Ignazio J., Camere M. A., Lewis D. E., Jorgensen D., Breen J. D., Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrobial Agents and Chemotherapy 2005 49 10 4035 4041 2-s2.0-25844433980 10.1128/AAC.49.10.4035-4041.2005 (Pubitemid 41400943)
33. Drehobl M. A., de Salvo M. C., Lewis D. E., Breen J. D., Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005 128 4 2230 2237 2-s2.0-27144535897 10.1378/chest.128.4.2230 (Pubitemid 41507564)
34. Sopena N., Martínez-Vázquez C., Rodríguez- Suárez J. R., Segura F., Valencia A., Sabrià M., Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. Journal of Chemotherapy 2004 16 1 102 103 2-s2.0-1942519217 (Pubitemid 38519741)
35. Baldwin D. R., Wise R., Andrews J. M., Ashby J. P., Honeybourne D., Azithromycin concentrations at the sites of pulmonary infection. European Respiratory Journal 1990 3 8 886 890 2-s2.0-0025610923
36. Léophonte P., File T., Feldman C., Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respiratory Medicine 2004 98 8 708 720 2-s2.0-3042589219 10.1016/j.rmed.2004.04. 007 (Pubitemid 38842773)
37. Li J. Z., Winston L. G., Moore D. H., Bent S., Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. American Journal of Medicine 2007 120 9 783 790 2-s2.0-34548172901 10.1016/j.amjmed.2007. 04.023 (Pubitemid 47313349)
38. Avdic E., Cushinotto L. A., Hughes A. H., Hansen A. R., Efird L. E., Bartlett J. G., Cosgrove S. E., Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia. Clinical Infectious Diseases 2012 54 11 1581 1587 10.1093/cid/cis242
39. Becker K. L., Snider R., Nylen E. S., Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Critical Care Medicine 2008 36 3 941 952 2-s2.0-44449113393 10.1097/CCM.0B013E318165BABB
40. Harbarth S., Holeckova K., Froidevaux C., Pittet D., Ricou B., Grau G. E., Vadas L., Pugin J., Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. American Journal of Respiratory and Critical Care Medicine 2001 164 3 396 402 2-s2.0-0035421655 (Pubitemid 32778205)
41. Schuetz P., Christ-Crain M., Thomann R., Falconnier C., Wolbers M., Widmer I., Neidert S., Fricker T., Blum C., Schild U., Regez K., Schoenenberger R., Henzen C., Bregenzer T., Hoess C., Krause M., Bucher H. C., Zimmerli W., Mueller B., Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. Journal of the American Medical Association 2009 302 10 1059 1066 2-s2.0-70149088214 10.1001/jama.2009.1297
42. Christ-Crain M., Jaccard-Stolz D., Bingisser R., Gencay M. M., Huber P. R., Tamm M., Müller B., Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. The Lancet 2004 363 9409 600 607 2-s2.0-1342265610 10.1016/S0140-6736(04)15591-8 (Pubitemid 38264177)
43. Christ-Crain M., Stolz D., Bingisser R., Müller C., Miedinger D., Huber P. R., Zimmerli W., Harbarth S., Tamm M., Müller B., Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. American Journal of Respiratory and Critical Care Medicine 2006 174 1 84 93 2-s2.0-33745471090 10.1164/rccm.200512-1922OC (Pubitemid 43955248)
44. Long W., Deng X., Zhang Y., Lu G., Xie J., Tang J., Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia. Respirology 2011 16 5 819 824 2-s2.0-79959875641 10.1111/j.1440-1843.2011.01978.x
45. Schuetz P., Briel M., Christ-Crain M., Stolz D., Bouadma L., Wolff M., Luyt C. E., Chastre J., Tubach F., Kristoffersen K. B., Wei L., Burkhardt O., Welte T., Schroeder S., Nobre V., Tamm M., Bhatnagar N., Bucher H. C., Mueller B., Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clinical Infectious Diseases 2012 55 5 651 662 10.1093/cid/cis464